En español

Hallucinogens and Dissociative Drugs


  1. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2012.
  2. Johnston, L.D.; O’Malley, P.M.; Bachman, J.G.; and Schulenberg, J.E. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2013. Ann Arbor: Institute for Social Research, the University of Michigan, 2014.
  3. Hibell, B.; Guttormsson, U.; Ahlström, S.; Balakireva, O.; Bjarnason, T.; Kokkevi, A.; and Kraus, L. The 2011 ESPAD Report: Substance Use Among Students in 36 European Countries. Stockholm, Sweden: The Swedish Council for Information on Alcohol and Other Drugs (CAN), 2012.
  4. Bogenschutz, M.P.; and Pommy, J.M. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal 4(7–8): 543–555, 2012.
  5. Bonson, K.R. Hallucinogenic Drugs. In Encyclopedia of Life Sciences, Nature Publishing Group, 2001.
  6. Passie, T.; Halpern, J.H.; Stichtenoth, D.O.; Emrich, H.M.; and Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci Ther 14(4): 295–314, 2008.
  7. Nichols, D.E. Hallucinogens. Pharmacol Ther 101(2): 131–181, 2004.
  8. Schindler, E.A.; Dave, K.D.; Smolock, E.M.; Aloyo, V.J.; and Harvey, J.A. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (+/-)-1-(2,5-dimethoxy- 4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacol Biochem Behav 101(1): 69–76, 2012.
  9. Lee, H.M.; and Roth, B.L. Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A 109(6): 1820–1821, 2012.
  10. Morgan, C.J.; Curran, H.V.; and Independent Scientific Committee on Drugs. Ketamine use: A review. Addiction 107(1): 27–38, 2012.
  11. Morris, B.J.; Cochran, S.M.; and Pratt, J.A. PCP: From pharmacology to modelling schizophrenia. Curr Opin Pharmaco 5(1):101–106, 2005.
  12. Cunningham, C.W.; Rothman, R.B.; and Prisinzano, T.E. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63(2): 316–347, 2011.
  13. MacLean, K.A.; Johnson, M.W; Reissig, C.J.; Prisinzano, T.E.; and Griffiths, R.R. Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl). 226(2): 381–392, 2013.

This page was last updated January 2014

Get this Publication

NIDA Notes: The Latest in Drug Abuse Research

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.